Do cytochrome enzymes influence the therapeutic effect of tropisetron in fibromyalgia?

Drugs under Experimental and Clinical Research

Volumn 29, Issue 2, 2003, Pages 91-94

  Stratz, T ^a   Kees, F ^b   Müller, Wolfgang ^a  

^a Hochrhein Inst fur Rehab Forsch   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; TROPISETRON;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG HALF LIFE; FEMALE; FIBROMYALGIA; HUMAN; OPEN STUDY; PAIN; TREATMENT OUTCOME;

ADULT; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; FIBROMYALGIA; HALF-LIFE; HUMANS; INDOLES; INJECTIONS, INTRAVENOUS; MIDDLE AGED; PILOT PROJECTS; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME;

EID: 0042528798     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. 3-Rezeptoren. Z. Rheumatol., 53, 225, 1994.
2. 3 receptor antagonist. Scand. J. Rheumatol., 29 (Suppl. 113), 49, 2000.
3. Späth M., Stratz T., Neeck G., et al. Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia. In preparation.
4. Müller W., Stratz T. Results of the intravenous administration of tropisetron in fibromyalgia patients. Scand. J. Rheumatol., 29 (Suppl. 113), 59, 2000.
5. Fischer V., Vickers A.E., Heitz F., et al. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and odansetron. Drug Metab. Dispos., 22, 269, 1994.
6. Harhangi B.S., Oostra B.A., Heutink P., van Duijn C.M., Hofman A., Breteler M.M. CYP2D6 polymorphism in Parkinson's disease: The Rotterdam Study. Mov. Disord., 16, 290, 2001.
7. Stefanovic M., Topic E., Ivanisevic A.M., Relja M., Korsic M. Genotyping of CYP2D6 in Parkinson's disease. Clin. Chem. Lab. Med., 38, 929, 2000.
8. Kees F., Färber L., Bucher M., Mair G., Morike K., Grobecker H. Pharmacokinetics of therapeutic doses of tropisetron in healthy volunteers. Br. J. Clin. Pharmacol., 52, 705, 2001.
9. Allorge D., Harlow J., Boulet O., et al. In-vitro analysis of the contribution of CYP2D6.35 to ultra-rapid metabolism. Pharmacogenetics, 11, 739, 2001.